GENERAL
Biocon Arm Secures Positive EMA Opinion For Pertuzumab Biosimilar
Biocon Biologics Ltd, a wholly-owned subsidiary of Biocon Ltd, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation for its Pertuzumab biosimilar, Pebrilzo, for the treatment of HER2-positive breast cancer. The product, available as a 420 mg concentrate solution for […]
CW Bureau
·
Sep 21, 2026
GENERAL
Biocon Biologics Secures Japan Govt Approval For Pegfilgrastim Biosimilar
Biocon Biologics Ltd, a wholly owned subsidiary of Biocon Ltd., has received marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, strengthening the company’s biosimilars portfolio in the Japanese market. The product is a biosimilar to Neulasta, a pegfilgrastim-based medicine used to reduce the risk of infection associated with […]
CW Bureau
·
Aug 25, 2026
GENERAL
Biocon Launches Interchangeable Eye Drug Biosimilar Yesafili In US Market
Biocon Ltd has commercially launched Yesafili, its interchangeable biosimilar to blockbuster eye drug Eylea (aflibercept) 2 mg, in the United States, marking a significant expansion of its ophthalmology portfolio in the world’s largest pharmaceutical market. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of various retinal disorders, including age-related macular […]
CW Bureau
·
Aug 3, 2026
GENERAL
Biocon Partner Bags Malaysia Insulin Contracts Worth Over MYR 225 Mn
Biocon Ltd, an innovation-led global biopharmaceutical company, said its long-standing partner, Duopharma Biotech Berhad, through its wholly owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin supply contracts from Malaysia’s Ministry of Health (MoH) worth more than MYR 225 million. Under the contracts, Biocon’s Malaysian subsidiary, Biocon Sdn. Bhd., will supply short-acting recombinant human […]
CW Bureau
·
Jun 24, 2026
